Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

42 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Preclinical efficacy of azacitidine and venetoclax for infant KMT2A-rearranged acute lymphoblastic leukemia reveals a new therapeutic strategy.
Cheung LC, Aya-Bonilla C, Cruickshank MN, Chiu SK, Kuek V, Anderson D, Chua GA, Singh S, Oommen J, Ferrari E, Hughes AM, Ford J, Kunold E, Hesselman MC, Post F, Faulk KE, Breese EH, Guest EM, Brown PA, Loh ML, Lock RB, Kees UR, Jafari R, Malinge S, Kotecha RS. Cheung LC, et al. Among authors: malinge s. Leukemia. 2023 Jan;37(1):61-71. doi: 10.1038/s41375-022-01746-3. Epub 2022 Nov 15. Leukemia. 2023. PMID: 36380143 Free PMC article.
Romidepsin enhances the efficacy of cytarabine in vivo, revealing histone deacetylase inhibition as a promising therapeutic strategy for KMT2A-rearranged infant acute lymphoblastic leukemia.
Cheung LC, Cruickshank MN, Hughes AM, Singh S, Chua GA, Ford J, Ferrari E, Oommen J, Malinge S, Lock RB, Kees UR, Kotecha RS. Cheung LC, et al. Among authors: malinge s. Haematologica. 2019 Jul;104(7):e300-e303. doi: 10.3324/haematol.2018.192906. Epub 2019 Jan 24. Haematologica. 2019. PMID: 30679330 Free PMC article. No abstract available.
Constitutive Activation of RAS/MAPK Pathway Cooperates with Trisomy 21 and Is Therapeutically Exploitable in Down Syndrome B-cell Leukemia.
Laurent AP, Siret A, Ignacimouttou C, Panchal K, Diop M, Jenni S, Tsai YC, Roos-Weil D, Aid Z, Prade N, Lagarde S, Plassard D, Pierron G, Daudigeos E, Lecluse Y, Droin N, Bornhauser BC, Cheung LC, Crispino JD, Gaudry M, Bernard OA, Macintyre E, Barin Bonnigal C, Kotecha RS, Geoerger B, Ballerini P, Bourquin JP, Delabesse E, Mercher T, Malinge S. Laurent AP, et al. Among authors: malinge s. Clin Cancer Res. 2020 Jul 1;26(13):3307-3318. doi: 10.1158/1078-0432.CCR-19-3519. Epub 2020 Mar 27. Clin Cancer Res. 2020. PMID: 32220889 Free PMC article.
Efficacy of DYRK1A inhibitors in novel models of Down syndrome acute lymphoblastic leukemia.
Carey-Smith SL, Simad MH, Panchal K, Aya-Bonilla C, Smolders H, Lin S, Armitage JD, Nguyen VT, Bentley K, Ford J, Singh S, Oommen J, Laurent AP, Mercher T, Crispino JD, Montgomery AP, Kassiou M, Besson T, Deau E, Meijer L, Cheung LC, Kotecha RS, Malinge S. Carey-Smith SL, et al. Among authors: malinge s. Haematologica. 2024 Feb 29. doi: 10.3324/haematol.2023.284271. Online ahead of print. Haematologica. 2024. PMID: 38426275 Free article.
DYRK1A regulates B cell acute lymphoblastic leukemia through phosphorylation of FOXO1 and STAT3.
Bhansali RS, Rammohan M, Lee P, Laurent AP, Wen Q, Suraneni P, Yip BH, Tsai YC, Jenni S, Bornhauser B, Siret A, Fruit C, Pacheco-Benichou A, Harris E, Besson T, Thompson BJ, Goo YA, Hijiya N, Vilenchik M, Izraeli S, Bourquin JP, Malinge S, Crispino JD. Bhansali RS, et al. Among authors: malinge s. J Clin Invest. 2021 Jan 4;131(1):e135937. doi: 10.1172/JCI135937. J Clin Invest. 2021. PMID: 33393494 Free PMC article.
SNAIL trail in myeloid malignancies.
Malinge S. Malinge S. Blood. 2020 Aug 20;136(8):920-921. doi: 10.1182/blood.2020006613. Blood. 2020. PMID: 32818247 Free article. No abstract available.
42 results